Quantcast
Last updated on April 23, 2014 at 12:38 EDT

Latest Merck Stories

2013-10-16 00:20:44

Alirocumab monotherapy reduced "bad" cholesterol three times more than ezetimibe PARIS and TARRYTOWN, N.Y., Oct. 16, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C,...

2013-10-11 23:19:25

On October 3, a New York federal judge delayed the transfer of hundreds of Fosamax lawsuits in the Multidistrict Litigation to give the manufacturer and plaintiffs the opportunity to reach a settlement. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Fosamax side effects. San Diego, CA (PRWEB) October 11, 2013 AttorneyOne.com, a recognized...

2013-10-10 16:26:58

NEW YORK, Oct. 10, 2013 /PRNewswire/ -- Morgan & Morgan is investigating whether Ariad Pharmaceuticals Inc. ("Ariad" or the "Company") (ARIA) and certain of its officers violated the federal securities laws when making statements to investors regarding its experimental drug Iclusig. On October 9, 2013, the Company updated the data from its PACE trial of Iclusig and revealed that the drug was shown to cause a higher rate of blood clots and heart-related side effects than...

2013-10-09 16:23:19

NEW YORK, Oct. 9, 2013 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Ariad Pharmaceuticals, Inc. ("Ariad" or the "Company") (NasdaqGS: ARIA). Such investors are advised to contact Peretz Bronstein or his investor Relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. The investigation concerns whether Ariad and certain of its officers and/or directors have...

2013-10-05 08:20:10

- Research grants reflect company's continuing commitment to multiple sclerosis (MS) community ROCKLAND, Mass. and COPENHAGEN, Denmark, Oct. 5, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today on the occasion of the 29(th) European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the recipients of the company's inaugural Grant for Multiple Sclerosis Innovation (GMSI). (Logo:...

2013-10-04 23:21:56

d’Oliveira & Associates has posted a new infographic which provides a list of side effects and timeline of events. The law firm works with some of the more experienced Zocor lawyers who handle these cases. (PRWEB) October 04, 2013 Zocor (simvastatin) helps control high cholesterol when combined with a healthy diet and exercise. The FDA approved this medicine in December 1991. It has also been approved in combination with drugs like Januvia (Juvisync) and Zetia (Vytorin). On March...

2013-10-02 23:19:21

Reportbuyer.com just published a new market research report: Global Vaccine Market Forecast to 2017. London (PRWEB) October 02, 2013 Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster...

2013-10-01 23:18:34

Harvard Business Publishing clients win awards in CLO Learning in Practice Awards competition. Merck wins Gold in the Global Learning category and Goodyear wins Bronze in the Trailblazer category with leadership development programs based on Leadership Direct. Boston, MA (PRWEB) October 01, 2013 Harvard Business Publishing today announced that last night’s CLO Learning in Practice awards reception yielded prestigious awards for two of its clients. Merck was named Gold winner in the...

2013-10-01 08:32:44

ROCKLAND, Mass., Oct. 1, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is the founding supporter of the newly launched Multiple Sclerosis (MS) Resource Centre website (http://multiplesclerosis.elsevierresource.com/) developed by Elsevier, B.V. of the Netherlands. EMD Serono helped established the MS Resource Centre through a $250,000 unrestricted grant to Elsevier, B.V. to develop and launch the website, which will provide high quality,...

2013-10-01 08:30:51

Company to Receive $3.3 Million One-Time Payment All amounts are in US dollars (unless otherwise mentioned) QUÉBEC CITY, Oct. 1, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the successful completion of its previously announced agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide(®) product. The principal outcome of such agreements is the transfer of...